vaccines

an Open Access Journal by MDPI

IMPACT FACTOR 3.4

Indexed in: PubMed

CITESCORE 9.9

SARS-CoV-2 Spike Protein: Pathogenesis, Variants, Immunogenicity, Vaccines, and Potential Therapies

Guest Editors:

Dr. Hanzhong Ke
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA

Dr. Zhaoqi Yan
Gladstone Institutes, San Francisco, CA 94158, USA

Deadline for manuscript submissions:
closed (31 December 2023)

Message from the Guest Editors

SARS-CoV-2 spike-based vaccines have been proven a huge success in eliciting protective humoral and cellular immunity and mitigating the disease. Since it first began circulating, the WHO has identified five variants of concern: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529). Omicron has further emerged into BA.1, BA.2, BA.2.12.1, BA.3, and BA.4/5 subvariants, which have displayed further immune escape, compromising current vaccine and antibody effectiveness.

1.Studies that broaden our current understandings of spike protein's roles in SARS-CoV-2 pathogenesis.

2. Insights into host humoral and cellular responses against spike proteins.

3. Novel approaches for spike mutation predictions and mechanisms of immune evasion.

4. Exploration of next-generation vaccine, pan-beta coronavirus vaccine, pan-human endemic coronavirus vaccine developments and potential anti-COVID therapies.

5. Interdisciplinary technologies or platforms to accelerate the development of new anti-COVID therapies.

vaccines

IMPACT FACTOR 3.4 | Indexed in: PubMed | CITESCORE 9.9

an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
𝕏@Vaccines_MDPI